California Institute of Technology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1891-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Can Computational Measures of Task Performance Predict Psychiatric Symptoms and Changes in Symptom Severity Across Time
- Conditions
- BehaviorDepressive DisorderAnxiety DisordersObsessive Compulsive Disorder (OCD)
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- California Institute of Technology
- Target Recruit Count
- 1100
- Registration Number
- NCT06705179
- Locations
- 🇺🇸
UCLA Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, United States
🇺🇸California Insitute of Technology, Pasadena, California, United States
News
Caltech's Smart Bandage Technology Demonstrates Early Biomarker Detection in First Human Clinical Trial
California Institute of Technology researchers successfully transitioned their iCares smart bandage system from animal models to human clinical testing, enrolling 20 patients with diabetic foot ulcers and venous leg wounds.
Nanorobots for Drug Delivery Market Set to Reach $1.73 Billion by 2030, Transforming Precision Medicine
The global nanorobots for drug delivery market is projected to grow from $1.22 billion in 2025 to $1.73 billion by 2030, representing a CAGR of 7.05% as demand for targeted therapeutic solutions increases.
Mosaic-8b Nanoparticle Vaccine Shows Promise Against Sarbecovirus Variants
A novel mosaic-8b nanoparticle vaccine is under development to provide broad cross-reactive immunity against known and future sarbecovirus strains, enhancing pandemic preparedness.